HeartCore Enterprises, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HeartCore Enterprises, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $30.41M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $21.85M | Mar 31, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.97M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $22.69M | Mar 31, 2026 |
| FY2023 | Dec 31, 2023 | $21.85M | Apr 9, 2024 |
| FY2023 | Dec 31, 2022 | $8.82M | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | $10.82M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $9.03M | Mar 31, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.15M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $14.72M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $8.07M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.35M | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | $5.19M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.02M | Mar 31, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.79M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.48M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($4.19M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.68M) | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | ($338.2K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $151.0K | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.12M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($161.7K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($4.12M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.70M) | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | $59.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $258.7K | Mar 31, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $179.8K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.02M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $641.0K | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | $510.7K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $311.0K | Mar 31, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.77M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($4.33M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.81M) | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | $766.3K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $745.7K | Mar 31, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.4K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $526.3K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $57.1K | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | $36.2K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $27.2K | Mar 31, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.06M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $13.97M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $19.62M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.14M | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | $9.12M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $10.36M | Mar 31, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.78M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $10.50M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $11.96M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.33M | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | $9.68M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $10.96M | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.78M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.65M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.17M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.81M | Apr 9, 2024 |
| FY2021 | Dec 31, 2021 | ($559.0K) | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | ($958.0K) | Mar 31, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $3.28M | Mar 31, 2025 |
| FY2023 | Sep 6, 2022 | $3.28M | Apr 9, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.76M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($16.24M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($14.76M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($10.57M) | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | ($3.90M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($3.56M) | Mar 31, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.99M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.97M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.01M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.18M | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | $3.14M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.06M | Mar 31, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $499.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $545.1K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.16M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.83M | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | $2.74M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.99M | Mar 31, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25.42M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 21.94M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 20.84M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 17.65M | Apr 9, 2024 |
| FY2022 | Dec 31, 2021 | 15.55M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 15.24M | Mar 31, 2022 |